ClinicalTrials.gg
CompletedNCT05877053Updated May 1, 2025

A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

A Phase 1 interventional study of CK-4021586 and Placebo for CK-4021586 in Healthy Participants, sponsored by Cytokinetics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by Cytokinetics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purposes of this study are to:

  • Learn about the safety and tolerability of CK 4021586 after a single dose and multiple doses in healthy subjects.
  • Find out how much CK-4021586 is in the blood after a single dose and multiple doses.
  • Determine the effect different doses of CK-4021586 on the pumping function of the heart.
  • Determine the effect of food in the stomach on how much CK-4021586 is in the blood after a single dose.
02

Conditions studied

  • Healthy Participants

Keywords

  • CK-586
  • CK-4021586
03

In context

Lead sponsor

Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants aged between 18 and 55 years (inclusive) with a between 18.0 and 30.0 kg/m2 (inclusive), with a body weight > 50.0 kg

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any significant metabolic, allergic/immunologic, dermatologic, hepatic, renal, hematologic, respiratory, cardiovascular (including arrhythmia), gastrointestinal, gallbladder/biliary, musculoskeletal, neurologic, or psychiatric disorder in the opinion of the Investigator or designee.
  • History of significant or allergy to any drug compound or other substance, unless approved by the Investigator and the Sponsor's Medical Monitor.
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, hernia repair, and/or cholecystectomy will be allowed).
  • Participants with breast implants that may impede echocardiography
  • illness within 4 weeks prior to check in.
  • Significant abnormalities (heart block, prolonged , arrhythmia)
  • History of, or current substance abuse (drug or alcohol), known drug or alcohol dependence within the last 2 years prior to Screening, or positive test for drugs of abuse during the screening period
  • Any acute or chronic condition that would limit the participant's ability to complete and/or participate in this clinical study, in the judgment of the Investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    CK-4021586 for SAD Cohort

    Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-4021586

    Drug: CK-4021586

  • Placebo comparator
    Placebo for SAD Cohort

    Subjects will be assigned to one of approximately 8 planned cohorts and receive single doses of placebo

    Drug: Placebo for CK-4021586

  • Experimental
    CK-4021586 for MAD Cohort

    Subjects will be assigned to one of 4 planned dose cohorts and receive multiple doses of CK-4021586

    Drug: CK-4021586

  • Placebo comparator
    Placebo for MAD Cohort

    Subjects will be assigned to one of approximately 4 planned cohorts and receive multiple of placebo

    Drug: Placebo for CK-4021586

  • Experimental
    Food Effect

    Healthy subjects will be administered CK-4021586 with and without food in a cross-over fashion

    Drug: CK-4021586

Interventions

  • DrugCK-4021586

    CK-4021586

  • DrugPlacebo for CK-4021586

    Placebo for CK-4021586

06

What researchers measure

Primary outcomes

  1. Incidence and severity of AEs

    To assess the safety and tolerability of CK-4021586 when administered orally as single or multiple doses to healthy participants

    Time frame: Time Frame for SAD Cohorts: Day -1 - Day 7; Time Frame for MAD Cohorts: Day -1 - Day 14; Time Frame for Food Effect Cohorts: Days 1 to 7 (Treatment Periods 1 and 2)

Secondary outcomes

  1. Primary PK parameters of CK-4021586 including AUC

    To characterize the PK of CK-4021586 and CK-4022235 after single and multiple oral doses in healthy participants

    Time frame: Time Frame for SAD Cohorts: Day -1 - Day 7; Time Frame for MAD Cohorts: Day -1 - Day 14; Time Frame for Food Effect Cohorts: Days 1 to 7 (Treatment Periods 1 and 2)

  2. Changes over time from baseline in echocardiographic parameters including, but not limited to, LVEF

    To characterize the PD effects of single and multiple oral doses of CK-4021586 in healthy participants

    Time frame: Time Frame for SAD Cohorts: Day -1 - Day 7; Time Frame for MAD Cohorts: Day -1 - Day 14

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Nov 2024, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2023
First posted
May 26, 2023
StartActual
May 9, 2023
Primary completionActual
Nov 20, 2024
CompletionActual
Nov 20, 2024
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05877053
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
May 26, 2023
Start date
May 9, 2023
Primary completion
Nov 20, 2024
Completion
Nov 20, 2024
Last update
May 1, 2025

Study contacts

Scientific Leadership at Cytokinetics
study director · Cytokinetics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion